Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.

被引：25

作者：

Corcoran, Ryan Bruce

Atreya, Chloe Evelyn

Falchook, Gerald Steven

Infante, Jeffrey R.

Hamid, Omid

Messersmith, Wells A.

Daud, Adil

Kwak, Eunice Lee

Ryan, David

Kurzrock, Razelle

Sun, Peng

Cunningham, Elizabeth Ann

Orford, Keith W.

Motwani, Monica

Bai, Yuchen

Patel, Kiran

Venook, Alan P.

Kopetz, Scott

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[5] Angeles Clin & Res Inst, Los Angeles, CA USA

[6] Univ Colorado, Ctr Canc, Aurora, CO USA

[7] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA

[8] Harvard Univ, Sch Med, Boston, MA USA

[9] Univ Calif San Diego, La Jolla, CA 92093 USA

[10] GlaxoSmithKline, Collegeville, PA USA

[11] Thomas Jefferson Univ, Collegeville, PA USA

[12] GlaxoSmithKline Res & Dev Ltd, Collegeville, PA USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.3517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

3517

引用

页数：1